No abstract

No abstract

Correspondence to Adam Gladwish, adam.gladwish@utoronto.ca SUMMARY Locally advanced lung cancer, if untreated, typically progresses although the rapidity of progression may vary. The authors report the case of an 84-year-old woman who presented with radiologically progressive, biopsy proven stage IIIB (T2N3) squamous cell carcinoma in the left lower lobe of the lung. Her disease was too advanced for curative treatment and in view of the lack of symptoms to palliate, she received no anticancer treatment. In follow-up, her tumour was noted to spontaneously regress in size on serial chest x-rays. Eight months after biopsy, restaging CT showed complete resolution of the enlarged biopsy proven mediastinal and hilar lymph nodes and signifi cant regression of the primary tumour. She remains clinically well.

Serial FDG-PET images during CRT show significant increases in SUVpeak for patients in whom RE develops. The changes at week 2 may predict those at risk for the development of grade 3 RE and may be informative for adaptive planning and early intervention.

No abstract

No abstract

1983 -87 (Sharp et al., 1993b, largely due to the introduction of platinum-based chemotherapy (Ellis and Sikora, 1987). The complete excision of residual masses following chemotherapy is now accepted practice with more experinced surgeons in this area more likely to perform adequate resection (Ewing et al., 1987;Hendry et al., 1987;Whillis et al., 1991). It has also been suggested that results of therapy for this diease in Scotland are better in centres where a large number of patients are seen (Harding et al., 1993). In Scotland there are five oncology centres, patients with NSGCT being treated in them all. The audit was designed to assess if there was any variation in the success of therapy across the country for this usually curable cancer.This audit, and those reported in the accompanying two papers (Clarke et al., 1995;Howard et al., 1995) were part of a Scottish National Audit assessing the appropriateness and variation in manag t strategies and success of therapy for testicular NSGCIT. The (Clarke et al., 1995). New registrations not referred to oncology centres were excluded from the survival analysis as their diagnosis had not been validated.The end of the follow-up period was defined as 31 December 1992 and survival time was caculated from date of diagnosis until death, or the end of follow-up. Actuarial survival curves based on Kaplan-Mewer estimates were described and the log rank chi-square test for differences in survival rates alculated. These data are summarised by means of the 5 year survival rates with associated standard error. Deaths from causes other than the disease or its treatment, as assessed by the reviewer in this study, were censored.As numbers of patients in some health boards were small these were grouped crudely according to population density to investigate area of residence at diagnosis of cancer. A priori the following groupings were defined (1)

No abstract